Natera Sees 15% Upside As BTIG Targets $270, Signatera Added To NCCN Guidelines
NTRA•BTIG lifted Natera’s price target to $270, reflecting a 15.01% potential increase based on ongoing growth. The NCCN updated bladder cancer guidelines to include Signatera MRD testing, and 21 Prospera presentations at the American Transplant Congress showcased a study where elevated signals predicted adverse events in over 18% of patients.
1. Price Target Increase
BTIG raised Natera’s price target to $270, representing roughly 15.01% upside from the $234.76 trading level. The revision reflects confidence in the company’s cell-free DNA testing growth and expanding clinical adoption.
2. Clinical Guideline Update
The NCCN updated bladder cancer guidelines to incorporate Signatera for molecular residual disease testing, marking the test’s integration into standard care protocols for monitoring treatment response.
3. Transplant Monitoring Focus
Natera will present 21 abstracts on its Prospera transplant monitoring test at the American Transplant Congress. Data from the PEDAL study show elevated Prospera signals predicted adverse events in over 18% of patients even when biopsies were negative.
4. Stock Performance Snapshot
Shares of Natera rose 2.60% to $234.76, trading within a 52-week range of $131.81 to $256.36. The company’s market capitalization stands at $33.62 billion with average daily volume of 1.51 million shares.
